Deep Value Reports

NTLA Stock Risk & Deep Value Analysis

Intellia Therapeutics, Inc.

DVR Score

8.8

out of 10

Hidden Gem

The Bottom Line on NTLA

We analyzed Intellia Therapeutics, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran NTLA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Sep 24, 2025•Run Fresh Analysis →

NTLA Deep Value Analysis

Intellia leverages a leading CRISPR gene-editing platform with groundbreaking *in vivo* clinical validation for ATTR, targeting vast underserved markets with curative potential. A strong IP moat, strategic partnerships, and substantial cash runway underpin its ambitious vision. Upcoming pivotal trial results and regulatory filings for lead assets are significant catalysts. While inherent biotech risks exist, the company demonstrates strong execution, a clear path to market leadership, and no fundamental 'dud' characteristics, making it a high-conviction, high-risk growth opportunity.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.

More Resources to Boost Your Portfolio

Explore our other guides and tools to maximize your investment returns

5-Minute Guide Thumbnail

6 Simple Steps Spotting Undervalued Stocks

Learn More
Dividend Stocks Thumbnail

Earn $500/Month with Dividend Stocks

Learn More
Swing Trading Guide Thumbnail

3 Swing Trading Strategies for Predictable Gains

Learn More